Our finding suggests that (a) the detection of MTAP deficiency in a small pancreatic biopsy will be representative of the entire tumor in the vast majority of cases, and (b) if drugs targeting MTAP-deficient cancers should be introduced into clinical practice the entire tumor mass should be amenable to these drugs in most patients. This evidence concerns the gene MTAP and neoplasm.